Lupin Q4 FY26 Results: Sales ₹73,919 Crore, PAT ₹14,604 Crore, Up 33% & 89% YoY
Lupin reported Q4 FY26 results with Net Sales at ₹73,919 crore (up 33% YoY) and Net Income at ₹14,604 crore (up 89% YoY). EBITDA grew 68% to ₹21,711 crore, with margins at 29.4%. North America sales surged 55%, while India grew 12%. The company completed the VISUfarma acquisition and received European Commission approval for biosimilar Ranibizumab.
Significant financial performance improvements, strategic acquisitions, and key regulatory approvals are material events that are likely to have a substantial impact on the company's valuation and market position.
The company reported strong year-on-year growth in sales, net income, and EBITDA, along with margin expansion. Key strategic acquisitions and regulatory approvals further bolster a positive outlook.
Lupin Limited announced its Audited Financial Results for the quarter and financial year ended March 31, 2026. The company reported a significant year-on-year growth, with Net Sales reaching ₹73,919 crore, an increase of 33%, and Net Income (PAT) surging by 89% to ₹14,604 crore. EBITDA also saw a substantial rise of 68% YoY to ₹21,711 crore, with the EBITDA margin improving to 29.4% from 23.2% in the previous year.
The company's performance was driven by strong growth across its key geographies. North America led with sales of ₹35,145 crore, up 55% YoY. India contributed ₹19,082 crore (up 12% YoY), followed by EMEA at ₹7,806 crore (up 19% YoY), ROW at ₹2,735 crore (up 37% YoY), APAC at ₹3,515 crore (up 9% YoY), LATAM at ₹3,144 crore (up 75% YoY), and API at ₹2,491 crore (up 8% YoY).
Key developments during the quarter included the completion of the acquisition of VISUfarma B.V., strengthening its European footprint, and the expansion of its Dabhasa manufacturing facility. Lupin also secured European Commission approval for its biosimilar Ranibizumab (RanluspecTM) and obtained US FDA tentative approvals for Dapagliflozin Tabs and Sugammadex Inj. The company filed 10+ ANDAs in FY26, including two 505(b)(2) applications, and plans to file over 15 in FY27. Lupin aims for over 100 new product launches by FY31, with over 65% of revenue from complex products.
Lupin highlighted its commitment to quality and regulatory compliance, with successful FDA inspections and responses submitted for ongoing matters. The company is also focusing on R&D, pivoting towards complex generics and biosimilars, with a target of launching 20 complex products in regulated markets by 2028. Financially, R&D expenditure stood at ₹5,898 crore (8.0% of sales) and Capex at ₹3,052 crore (4.1% of sales) for Q4 FY26. The Net Debt to Equity ratio improved to -0.21.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.